奥妥珠单抗联合来那度胺治疗复发/难治性滤泡性B细胞淋巴瘤(GALEN):多中心单臂2期研究
GALEN研究为多中心单臂2期试验,纳入89例既往接受过含利妥昔单抗治疗的复发/难治性滤泡性淋巴瘤患者,评估来那度胺联合奥妥珠单抗的活性与安全性。86例可评估患者中,68例(79%,95%CI 69-87)在诱导结束时达到总体缓解,达到预设主要终点;2年无事件生存率62%、无进展生存率65%、缓解持续时间70%、总生存率87%。最常见不良事件为乏力、中性粒细胞减少、支气管炎、腹泻和肌肉痉挛,安全性总体可控。
要点
- 诱导结束时总体缓解率79%(68/86,95%CI 69-87),完全缓解率38%(33/86,95%CI 28-50)。
- 2年无事件生存率62%、无进展生存率65%、缓解持续时间70%、总生存率87%。
- 3级及以上中性粒细胞减少最常见,4例(5%)发生发热性中性粒细胞减少,1例治疗相关死亡。
核心结论
- 来那度胺联合奥妥珠单抗在既往治疗的复发/难治性滤泡性淋巴瘤患者中具有活性,包括早期复发患者,且安全性可控。
- 需要开展随机试验,比较GALEN方案或以其为骨架的新免疫调节方案与来那度胺联合利妥昔单抗。
研究设计与样本
- 多中心、单臂、2期研究,纳入法国24个淋巴瘤学术研究组织中心。
- 纳入年龄≥18岁、组织学确诊CD20阳性复发/难治性滤泡性淋巴瘤(WHO 1、2或3a级)、ECOG 0-2、既往至少接受过一种含利妥昔单抗治疗的患者。
- 2014年6月11日至2015年12月18日共招募89例,86例可评估疗效,88例可评估安全性。
- 治疗方案:诱导期口服来那度胺20 mg联合静脉奥妥珠单抗1000 mg,共6个28天周期;第1年维持来那度胺10 mg(每28天周期第2-22天)联合奥妥珠单抗1000 mg(隔周期);第2年维持奥妥珠单抗1000 mg,共6个56天周期(第1天)。
- 主要终点为诱导结束时按1999年国际工作组标准由研究者评估的总体缓解比例;次要终点包括无事件生存、无进展生存、总生存和安全性。
主要发现
- 86例可评估患者中68例(79%,95%CI 69-87)在诱导结束时达到总体缓解,达到预设主要终点。
- 诱导结束时33例(38%,95%CI 28-50)达到完全缓解;诱导期间和整个治疗期间分别有70例(81%,95%CI 72-89)和72例(84%,95%CI 74-91)达到最佳总体缓解。
- 2年时无事件生存率62%(95%CI 51-72)、无进展生存率65%(95%CI 54-74)、缓解持续时间70%(95%CI 57-79)、总生存率87%(95%CI 78-93)。
关键数值与推荐
- 最常见不良事件:乏力54例(61%)、中性粒细胞减少38例(43%)、支气管炎36例(41%)、腹泻35例(40%)、肌肉痉挛34例(39%)。
- 3级及以上毒性以中性粒细胞减少最常见;4例(5%)发生发热性中性粒细胞减少。
- 88例患者中30例(34%)报告57起严重不良事件,最常见为基底细胞癌5例(6%)、发热性中性粒细胞减少4例(5%)、输注相关反应3例(3%)。
- 1例患者死于治疗相关发热性中性粒细胞减少。
临床怎么用
- 来那度胺联合奥妥珠单抗可作为既往治疗的复发/难治性滤泡性淋巴瘤患者的治疗选择,包括早期复发患者。
- 治疗期间需关注中性粒细胞减少及发热性中性粒细胞减少,以及乏力、支气管炎、腹泻、肌肉痉挛等不良事件。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenalidomide plus rituximab is approved to treat patients with relapsed or refractory follicular lymphoma. Obinutuzumab has been shown to enhance antibody-dependent cellular cytotoxicity, phagocytosis, and direct B-cell killing better than rituximab. Our aim was to determine the activity and safety of lenalidomide plus obinutuzumab in previously treated patients with relapsed or refractory follicular lymphoma. METHODS: In this multicentre, single-arm, phase 2 study, patients were enrolled from 24 Lymphoma Academic Research Organisation centres in France. Eligible patients (age ≥18 years) had histologically confirmed CD20-positive relapsed or refractory follicular lymphoma of WHO grade 1, 2, or 3a; an ECOG performance status of 0-2; and received at least one previous rituximab-containing therapy. Patients received oral lenalidomide (20 mg) plus intravenously infused obinutuzumab as induction therapy (1000 mg; six 28-day cycles), 1-year maintenance with lenalidomide (10 mg; 12 28-day cycles; days 2-22) plus obinutuzumab (1000 mg; alternate cycles), and 1-year maintenance with obinutuzumab (1000 mg; six 56-day cycles; day 1). The primary endpoint was the proportion of patients who achieved an overall response at induction end as per investigator assessment using the 1999 international working group criteria. The secondary endpoints were event-free survival, progression-free survival, overall survival, and safety. Analyses were per-protocol; the efficacy population included all patients who received at least one dose of both obinutuzumab and lenalidomide, and the safety population included all patients who received one dose of either investigational drug. The study is registered with ClinicalTrials.gov, number NCT01582776, and is ongoing but closed to accrual. FINDINGS: Between June 11, 2014, and Dec 18, 2015, 89 patients were recruited and 86 patients were evaluable for efficacy and 88 for safety. Median follow-up was 2·6 years (IQR 2·2-2·8). 68 (79%) of 86 evaluable patients (95% CI 69-87) achieved an overall response at induction end, meeting the prespecified primary endpoint. At 2 years, event-free survival was 62% (95% CI 51-72), progression-free survival 65% (95% CI 54-74), duration of response 70% (95% CI 57-79), and overall survival 87% (95% CI 78-93). Complete response was achieved by 33 (38%, 95% CI 28-50) of 86 patients at induction end, and the proportion of patients achieving a best overall response was 70 (81%, 95% CI 72-89) and 72 (84%, 74-91) of 86 patients during induction and treatment, respectively. The most common adverse events were asthenia (n=54, 61%), neutropenia (n=38, 43%), bronchitis (n=36, 41%), diarrhoea (n=35, 40%), and muscle spasms (n=34, 39%). Neutropenia was the most common toxicity of grade 3 or more; four (5%) patients had febrile neutropenia. 57 serious adverse events were reported in 30 (34%) of 88 patients. The most common serious adverse events were basal cell carcinoma (n=5, 6%), febrile neutropenia (n=4, 5%), and infusion-related reaction (n=3, 3%). One patient died due to treatment-related febrile neutropenia. INTERPRETATION: Our data shows that lenalidomide plus obinutuzumab is active in previously treated patients with relapsed or refractory follicular lymphoma, including those with early relapse, and has a manageable safety profile. Randomised trials of new immunomodulatory regimens, such as GALEN or using GALEN as a backbone, versus lenalidomide plus rituximab, are warranted. FUNDING: Lymphoma Academic Research Organisation, and Celgene and Roche.
引用
- Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019. PMID: 31296423. doi:10.1016/S2352-3026(19)30089-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。